Taro Pharmaceutical Industries Ltd. (TARO)

TARO Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Year Ending	TTM	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Net Income	53.87	53.87	25.45	58.27	-386.65	244.24
Depreciation & Amortization	31.09	31.09	32.13	25.92	23.68	21.38
Other Operating Activities	39.59	39.59	-25.82	-242.88	408.74	5.98
Operating Cash Flow	124.56	124.56	31.75	-158.7	45.77	271.61
Operating Cash Flow Growth	292.30%	292.30%	-	-	-83.15%	-16.10%
Capital Expenditures	-53.97	-53.97	-17.55	-11.8	-16.99	-26.63
Acquisitions	-	-	-1.98	-91.87	0.01	0.02
Change in Investments	138.56	138.56	-107.71	-66.67	84.89	-269.77
Other Investing Activities	-0.25	-0.25	1.68	-0.24	-0.16	-1.78
Investing Cash Flow	84.34	84.34	-125.56	-170.58	67.74	-298.16
Share Issuance / Repurchase	-	-	0	-24.93	-24.2	-26.98
Financing Cash Flow	0	0	0	-24.93	-24.2	-26.98
Exchange Rate Effect	-0.48	-0.48	-2.83	0.17	2.51	-0.56
Net Cash Flow	208.42	208.42	-96.64	-354.04	91.82	-54.1
Free Cash Flow	70.58	70.58	14.2	-170.5	28.78	244.97
Free Cash Flow Growth	397.18%	397.18%	-	-	-88.25%	-17.43%
Free Cash Flow Margin	11.22%	11.22%	2.48%	-30.37%	5.24%	37.99%
Free Cash Flow Per Share	1.88	1.88	0.38	-4.53	0.75	6.37

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).